Hi, doni. Your points are well taken. And something similar to this could be in our future?

FAIRFIELD, N.J.--(BUSINESS WIRE)--April 13, 2005--Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it has completed a $3 million private placement with Fusion Capital Fund II, LLC ('Fusion'). In conjunction with the private placement, Unigene has elected to terminate its common stock purchase agreement with Fusion, dated October 9, 2003, as amended.


Under the private placement, Unigene sold 2,123,142 shares of common stock and a five-year common stock purchase warrant to purchase up to 1,061,571 shares of common stock at an exercise price of $1.77 per share to Fusion. The common stock and warrant shares are not registered for sale and Unigene will file a registration statement covering the sale of the purchase shares and the warrant shares. A description of this transaction is provided in our Form 8-K filed on April 13, 2005.
'Fusion Capital, a long-standing investor in the company, has provided significant and timely financial support to Unigene in the past and we are pleased that they have decided to increase their ownership in Unigene,' commented Dr. Warren P. Levy, President and CEO of Unigene. 'We believe that our future financial requirements primarily will be met through sales of our nasal calcitonin product, which is currently awaiting approval by the FDA, and milestones from agreements with pharmaceutical partners, including GlaxoSmithKline, Novartis and Upsher-Smith.'
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusi"
Otcbb News and Informatuion About the OTCBB trading platform, and listing information.